Exploratory 4-year Analysis Continues to Support Adding 3 Years of Ribociclib to Adjuvant NSAI for HR-positive, HER2-negative EBC at Risk of Recurrence By Ogkologos - October 8, 2025 53 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the NATALEE study Source RELATED ARTICLESMORE FROM AUTHOR A Short-Course Dose Escalation Strategy Could Improve Ability to Reach Target Dose of Adjuvant Abemaciclib in High-Risk Early-Stage HR-positive, HER2-negative Breast Cancer FDA Approves Ziftomenib for Relapsed or Refractory Acute Myeloid Leukaemia with a NPM1 Mutation NEPA Plus Dexamethasone Provide Superior Chemotherapy-Induced Nausea and Vomiting Prevention Compared with SoC Antiemetic Prophylaxis MOST POPULAR 24-Year-Old Woman with Terminal Breast Cancer Dreams of Fairytale Wedding with... April 16, 2019 How to Cope With Taking Long-Term Medication June 27, 2023 Lymph Node Biopsies Are Unnecessary For Early-Stage Breast Cancer Patients, Study... January 7, 2020 Heart Problems: Investigating the Cardiac Side Effects of Cancer Treatments September 21, 2018 Load more HOT NEWS Prostate cancer: Lessons Learned from My Breast Cancer EMA Recommends Extension of Indications for Tislelizumab to First-Line Treatment of... Olivia Newton-John Talks About Her Use Of Medical Cannabis During Cancer... Electronic Symptom Monitoring with PROs Improves Patient-Reported Physical Function, Symptom Control,...
